FRM
XERS icon

Fox Run Management’s Xeris Biopharma Holdings XERS Stock Holding History

Fox Run Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$140K Sell
17,727
-13,994
-44% -$89.4K 0.02% 850
2026
Q1 		$178K Buy
31,721
+5,547
+21% +$36.8K 0.03% 779
2025
Q4 		$205K Buy
+26,174
New +$206K 0.03% 799

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fox Run Management's XERS Position: Q2 2026 in Review

Fox Run Management reduced its Xeris Biopharma Holdings (XERS) stake by 44% in Q2 2026, selling an estimated $89.4K and leaving 17,727 shares worth $140K. The position accounts for 0.02% of the portfolio, ranked #850.

Fox Run Management first reported a position in XERS in Q4 2025 and has held it in 3 quarters since. The position peaked at $205K in Q4 2025. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Fox Run Management held 17,727 shares of Xeris Biopharma Holdings worth $140K as of Q2 2026.
  • Fox Run Management sold 13,994 Xeris Biopharma Holdings shares in Q2 2026, an estimated $89.4K.
  • Xeris Biopharma Holdings made up 0.02% of Fox Run Management's portfolio in Q2 2026, its #850 holding.
  • Fox Run Management first reported a position in Xeris Biopharma Holdings in Q4 2025 and has held it in 3 quarters since.
  • Fox Run Management's Xeris Biopharma Holdings position peaked at $205K in Q4 2025.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.